Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIKIOTCMKTS:BIOQOTCMKTS:CBWTFOTCMKTS:SPHRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIKIAIkido Pharma$4.86-7.6%$4.76$3.31▼$11.48$26.66M0.9379,326 shs111,471 shsBIOQBioqual$44.25$49.81$44.25▼$72.50$39.56M-0.1578 shsN/ACBWTFAuxly Cannabis Group$0.06+1.7%$0.06$0.02▼$0.07$79.36M0.971.09 million shs176,155 shsSPHRYStarpharma$0.61$0.58$0.47▼$0.80$25.46M0.761,494 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIKIAIkido Pharma-3.66%+8.23%-8.04%+11.68%+144.65%BIOQBioqual0.00%0.00%-3.70%-26.25%-38.97%CBWTFAuxly Cannabis Group+1.69%+1.01%-8.79%+15.33%+180.00%SPHRYStarpharma0.00%+19.29%+6.78%-3.36%-15.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIKIAIkido PharmaN/AN/AN/AN/AN/AN/AN/AN/ABIOQBioqualN/AN/AN/AN/AN/AN/AN/AN/ACBWTFAuxly Cannabis Group0.6259 of 5 stars0.05.00.00.02.20.00.0SPHRYStarpharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIKIAIkido Pharma 0.00N/AN/AN/ABIOQBioqual 0.00N/AN/AN/ACBWTFAuxly Cannabis Group 0.00N/AN/AN/ASPHRYStarpharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIKIAIkido Pharma$10K2,665.71N/AN/A$19.27 per share0.25BIOQBioqual$58.59M0.68N/AN/AN/A∞CBWTFAuxly Cannabis Group$74.87M1.06N/AN/A$0.04 per share1.51SPHRYStarpharma$6.40M3.98N/AN/A$0.45 per share1.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIKIAIkido Pharma-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/ABIOQBioqual$480K-$2.39N/A∞N/A-5.54%-7.50%-4.90%N/ACBWTFAuxly Cannabis Group-$32.97M$0.01N/A∞N/A-65.48%-80.40%-28.61%N/ASPHRYStarpharma-$5.36MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest SPHRY, CBWTF, BIOQ, and AIKI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CBWTFAuxly Cannabis GroupN/A$0.01N/A$0.01N/AN/A4/11/2025Q3 2025BIOQBioqualN/A$1.05N/A$1.05N/A$14.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIKIAIkido PharmaN/AN/AN/AN/AN/ABIOQBioqual$0.501.13%N/AN/A N/ACBWTFAuxly Cannabis GroupN/AN/AN/AN/AN/ASPHRYStarpharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIKIAIkido PharmaN/A29.5429.54BIOQBioqualN/A3.733.73CBWTFAuxly Cannabis Group0.370.850.48SPHRYStarpharma0.074.944.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIKIAIkido Pharma10.88%BIOQBioqualN/ACBWTFAuxly Cannabis GroupN/ASPHRYStarpharmaN/AInsider OwnershipCompanyInsider OwnershipAIKIAIkido Pharma8.60%BIOQBioqual39.24%CBWTFAuxly Cannabis Group4.60%SPHRYStarpharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIKIAIkido Pharma45.49 million5.01 millionNot OptionableBIOQBioqual114894,000543,000Not OptionableCBWTFAuxly Cannabis Group3691.32 billion1.25 billionNot OptionableSPHRYStarpharma4541.82 millionN/ANot OptionableSPHRY, CBWTF, BIOQ, and AIKI HeadlinesRecent News About These CompaniesChange in Substantial Holder’s Voting Power at Starpharma HoldingsJune 3, 2025 | tipranks.comPleasing Signs As A Number Of Insiders Buy Starpharma Holdings StockMay 5, 2025 | uk.finance.yahoo.comStarpharma Advances Strategic Initiatives and Expands Market PresenceApril 29, 2025 | tipranks.comIs Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?March 25, 2025 | finance.yahoo.comRobmar Investments Acquires Substantial Stake in Starpharma HoldingsMarch 17, 2025 | tipranks.comStarpharma Highlights DEP® Dendrimer Platform at PepTalk ConferenceJanuary 15, 2025 | tipranks.comAstodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comStarpharma CEO Receives Major Performance Rights IssuanceDecember 12, 2024 | markets.businessinsider.comStarpharma Issues Unquoted Securities to Boost Employee IncentivesDecember 12, 2024 | markets.businessinsider.comStarpharma Holdings Reports Successful AGM ResultsNovember 29, 2024 | tipranks.comStarpharma Holdings Schedules Reconvened AGM for Key VoteNovember 26, 2024 | tipranks.comStarpharma AGM Results Highlight Voting ChallengesNovember 26, 2024 | tipranks.comStarpharma Holdings Highlights Strategic Advances in 2024November 25, 2024 | tipranks.comStarpharma Highlights Dendrimer Technology at Healthcare ConferenceNovember 18, 2024 | markets.businessinsider.comStarpharma Showcases Dendrimer Innovations at Microcap ConferenceOctober 29, 2024 | markets.businessinsider.comMedicxi, Starpharma create Petalion with $25M roundApril 9, 2024 | bioworld.comMedicxi and Starpharma to develop dendrimer-based cancer treatmentsApril 8, 2024 | pharmaceutical-technology.comStarpharma Holdings Ltd. ADRMarch 14, 2024 | wsj.comNews - StarpharmaFebruary 20, 2024 | thepharmaletter.comStarpharma at stalemate with FDA on VivaGelFebruary 20, 2024 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPHRY, CBWTF, BIOQ, and AIKI Company DescriptionsAIkido Pharma NASDAQ:AIKI$4.86 -0.40 (-7.60%) As of 06/13/2025AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Bioqual OTCMKTS:BIOQ$44.25 0.00 (0.00%) As of 06/13/2025Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.Auxly Cannabis Group OTCMKTS:CBWTF$0.06 +0.00 (+1.69%) As of 06/13/2025 03:42 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.Starpharma OTCMKTS:SPHRY$0.61 0.00 (0.00%) As of 06/13/2025Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
